Bayer stock holds near 49 euros as Q2 2026 earnings and Crop Science targets support outlook

Published on 09/03/2026 at 07:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock is trading close to 49 euros on Xetra as investors weigh a Q2 2026 earnings beat, lower debt guidance and ambitious Crop Science cash flow and margin targets through 2029.

Schwarzweiß-Dokumentarfoto einer großen Chemieanlage am Flussufer mit Rohrleitungen und Türmen — Bayer AG (DE000BAY0017): dokumentarische Schwarzweiß-Reportage-Aufnahme einer großen Chemiefabrik am Rheinufer mit hohen Türmen, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) stock recently traded at about 49.18 euros on Xetra as of September 2, 2026, placing the German healthcare and crop science group close to its current trading range while investors digest a stronger second quarter and updated divisional targets.

Q2 2026 figures and guidance underpin Bayer stock

According to an analysis on ad-hoc-news.de dated early September 2026, Bayer generated group sales of 10.87 billion euros in the second quarter of 2026, with adjusted EBITDA of 2.14 billion euros for the period ended June 30, 2026.

The same review notes that this 2.14 billion euros in adjusted EBITDA represented a 1.9 percent improvement versus the prior year quarter, while analysts had expected a decline of roughly 8 percent, turning the quarter into a clear positive surprise for operating performance and supporting sentiment toward Bayer stock.

Management used the backdrop of stronger operations and capital inflows to reduce its 2026 net financial debt guidance to a corridor of 29 to 30 billion euros, down from a previously communicated range of 32 to 33 billion euros, which investors see as an important step in balancing growth investment with deleveraging.

For the full year 2026, Bayer continues to guide to adjusted EBITDA between 9.6 billion and 10.1 billion euros and core earnings per share between 4.30 and 4.90 euros, providing the market with a clearer view of earnings power and the potential for further balance sheet improvement.

Analyst targets and same-day price context

Market data compiled by ad-hoc-news.de as of late August 2026 showed Bayer stock trading on Xetra around 48.67 euros, up about 31.5 percent since the start of 2026, highlighting that the shares have already priced in a meaningful part of the operational recovery while still leaving room for further moves if execution stays on track.

In the wake of the second-quarter results, consensus data reported by ad-hoc-news.de and based on MarketScreener as of September 1, 2026 indicated that the mean recommendation on Bayer stood at Outperform from 18 analysts, with an average target price of 57.39 euros versus the then recent close of 48.67 euros on Xetra, implying upside of about 17.91 percent from that price level.

A more granular look at the current trading snapshot shows Bayer shares last quoted at 49.18 euros on Xetra on September 2, 2026, 0.61 percent above the previous close of 48.88 euros, with parallel indications around 49.22 euros in Frankfurt and 49.08 euros in Stuttgart, underscoring that the stock is holding close to 49 euros across German trading venues.

Within the wider market, Bayer remains one of the major chemicals and pharmaceuticals names in the DAX index, and recent data show the DAX Performance Index trading at around 25,858.1 points as of September 3, 2026, modestly higher than the previous day, which provides a broadly supportive backdrop for large German blue chips such as Bayer.

Go deeper

More Bayer stock news and figures

For additional headlines, chart data and background on Bayer stock, the topic page at ad-hoc-news.de provides a compact overview of recent company news and market reactions.

Bayer stock on ad-hoc-news.de Investor Relations

Crop Science targets add medium term perspective

Beyond the group level guidance, Bayer has sharpened its medium term ambitions for the Crop Science division, which plays a central role in driving growth and funding deleveraging.

At a 2026 innovation event in Iowa, Bayer Crop Science outlined that it is targeting more than 3.0 billion euros in free operating cash flow by 2029, supported by 3.5 billion euros in incremental sales, over 1.0 billion euros in margin improvements and more than 1.5 billion euros in cumulative working capital cash release between 2024 and 2029.

The same presentation reaffirmed that for 2026 the division is guiding to a clean EBITDA margin in a range of 20 to 22 percent and aims for a mid 20s percent clean EBITDA margin by the end of the decade, signaling that productivity measures and portfolio moves should steadily lift profitability if market conditions cooperate.

For stock market investors, these Crop Science targets provide a structured path linking near term earnings and cash generation to longer term deleveraging and shareholder value, though execution risks around product launches, pricing and regulatory environments remain a key factor to monitor.

Representative Bayer product in focus

A representative product area illustrating Bayer's strategic focus is its portfolio of crop protection and seeds within the Crop Science division, which underpins the incremental sales and cash flow goals set out for 2024 to 2029.

Recent communications around Crop Science emphasize innovation in seeds and traits as well as new agrochemical solutions that are intended to support above market sales growth while sustaining the targeted clean EBITDA margin in the mid 20s percent range by the end of the decade.

Bayer stock price level and investor view

With Bayer stock recently quoted at 49.18 euros on Xetra as of September 2, 2026, the shares trade modestly above a 50 day moving average around 48.58 euros reported by ad-hoc-news.de, reflecting a market stance that acknowledges improved earnings and lower debt guidance but still awaits further proof that Crop Science and the wider group can deliver the full potential outlined in management's plans.